Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

20151,863 citationsJournal Articlebronze Open Access

Authors

Andrew W. Roberts · The Royal Melbourne Hospital

Matthew S. Davids · Dana-Farber Cancer Institute

John M. Pagel · Swedish Medical Center

Brad S. Kahl · Washington University in St. Louis

Soham D. Puvvada · University of Arizona

John F. Gerecitano · Cornell University

Thomas J. Kipps

Abstract

Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features. (Funded by AbbVie and Genentech; ClinicalTrials.gov number, NCT01328626.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 4, pp. 311-322

DOI: 10.1056/nejmoa1513257

Field-Weighted Citation Impact: 100.41